Community-Engaged and Health Services Research

Source: UWF – Wisconsin Partnership – MERC

Principal Investigator: Randall Brown; Christopher Nicholas Co-I; Bri Deyo Program Manager

Description: The long-term goal for this and future work is the dissemination of interventions effective in preventing opioid addiction and related complications, such as overdose, among victims of traumatic injury. The research specifically aims to engage the high-risk population of traumatic injury victims to develop an implementable set of opioid risk screening items.


Brown, R. T., Deyo, B., Nicholas, C., Baltes, A., Hetzel, S., Tilhou, A., Quanbeck, A., Glass, J., O’Rourke, A., & Agarwal, S. (2022). Screening in Trauma for Opioid Misuse Prevention (STOMP): Results from a prospective cohort of victims of traumatic injury. Drug and alcohol dependence232, 109286.

Brown, R., Deyo, B., Riley, C., Quanbeck, A., Glass, J. E., Turpin, R., Hetzel, S., Nicholas, C., Cruz, M., & Agarwal, S. (2017). Screening in Trauma for Opioid Misuse Prevention (STOMP): study protocol for the development of an opioid risk screening tool for victims of injury. Addiction science & clinical practice12(1), 28.

Funding Source: UW-Madison Department of Family Medicine and Community Health

Principal Investigator: Alyssa Tilhou

Description: The research aims to evaluate how people who use drugs (PWUD) modify drug use behavior in response to the use of fentanyl test strips (FTS). Utilizing interviews and surveys to gather information directly from PWUD, findings will yield insight into the safety of FTS as well as highlight behaviors perceived as feasible among PWUD to minimize the risk of harm. A secondary goal of this study is to provide knowledge about the penetration of fentanyl into the drug supply and provide information that can guide interventions to decrease the risk of overdose.

Psychedelic and MDMA Studies

Source: Multidisciplinary Association for Psychedelic Studies

Site Investigators: Christopher Nicholas, Randall Brown

Description: This multi-site study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants who were enrolled in a parent study for treatment of posttraumatic stress disorder (PTSD).

More Information »

Funding Source: Usona

Principal Investigator: Charles Raison (School of Human Ecology); Randall Brown Site PI; Christopher Nicholas Co-I; Bri Deyo Program Manager

Description: The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 8 post-dose.

Source: Multi-Disciplinary Association for Psychedelic Studies (MAPS)

Principal Investigator: Rick Doblin (MAPS); Randall Brown & Christopher Nicholas Co-Site PI; Bri Deyo Program Manager

Description: This multi-site double-blind, placebo-controlled randomized Phase 3 study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy versus psychotherapy with placebo in participants diagnosed with at least severe posttraumatic stress disorder (PTSD).


Mitchell, J.M., Bogenschutz, M., Lilienstein, A…Nicholas, C.R…Brown, R. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033.

Nicholas, C. R., Wang, J. B., Coker, A., Mitchell, J. M., Klaire, S. S., Yazar-Klosinski, B., Emerson, A., Brown, R. T., & Doblin, R. (2022). The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug and alcohol dependence233, 109356.

Funding Source: Gift from Mike and Sue Shannon

Principal Investigator: Christopher Nicholas, Chuck Raison (co-I)

Description: The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the therapeutic effects of psilocybin by investigating the amnestic effects of combined psilocybin and repeated boluses of midazolam.

More Information »


Contact Us

Megan Ringo
Program Manager
Email: Contact »

Program Office

UW Dept. of Family Medicine
610 N Whitney Way, STE 200
Madison, WI 53705-2700